PepperLedger
COMPOUND LIBRARY·VIP
COMPOUND PROFILE · PEPPERLEDGER

VIP (Vasoactive Intestinal Peptide)

Type
28-amino-acid endogenous neuropeptide hormone — naturally produced throughout the nervous system and immune tissues
Class
Anti-inflammatory neuropeptide · Immune modulator · Vasodilator · Gut motility regulator · Circadian rhythm regulator
Administration
Intranasal spray (primary route for CNS/immune applications — Shoemaker Protocol) · IV infusion (pulmonary hypertension trials)
Half-life
~2 minutes in plasma — extremely short; intranasal delivery to CNS bypasses rapid plasma clearance via olfactory pathway
Most studied use
MCAS (mast cell activation syndrome) · Long COVID · Chronic Inflammatory Response Syndrome (CIRS) · Pulmonary hypertension · Gut motility
Regulatory status
Not FDA-approved for MCAS, long COVID, or immune applications · IV Aviptadil has had Emergency Use Authorization for COVID-19 ARDS · Research chemical for intranasal use
Human evidence
Moderate — IV Aviptadil COVID-19 ARDS RCT, pulmonary hypertension Phase II RCT, Shoemaker Protocol clinical experience for MCAS/CIRS
Preclinical evidence
Exceptional — one of the most studied anti-inflammatory neuropeptides with deep mechanistic literature

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is VIP?

VIP (Vasoactive Intestinal Peptide) is one of the most potent endogenous anti-inflammatory neuropeptides in the human body. Naturally produced by neurons throughout the enteric nervous system, the CNS, and in immune cells, VIP serves as a systemic homeostatic signal — preventing excessive immune activation, maintaining gut motility, regulating circadian rhythms, and protecting neural tissue from inflammatory damage. Its plasma half-life is roughly 2 minutes, which is why physiological VIP operates locally and intranasally delivered VIP targets CNS receptors via the olfactory pathway.

VIP's community is distinctive: it's driven primarily by people with MCAS (mast cell activation syndrome), long COVID, and Chronic Inflammatory Response Syndrome (CIRS) — conditions characterized by dysregulated inflammatory responses that conventional medicine has limited tools to address. The Ritchie Shoemaker protocol — a structured approach to treating CIRS — uses intranasal VIP as a key intervention, creating a specific and knowledgeable user community around this application.

The mechanistic case for VIP in these conditions is genuinely strong. VIP directly inhibits mast cell degranulation — the pathological event in MCAS. It suppresses NF-κB inflammatory signaling, reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-12), promotes Treg activity, and shifts immune responses from Th1/Th17 toward anti-inflammatory Th2/Treg profiles. For conditions driven by mast cell hyperactivation or immune dysregulation, VIP addresses the underlying mechanism rather than just managing symptoms.

How it works

VPAC Receptor Signaling and Mast Cell Inhibition

VIP acts through VPAC1 (widely expressed in immune cells, lung, brain, GI tract) and VPAC2 (T lymphocytes, smooth muscle, pancreas). Receptor activation drives adenylyl cyclase → cAMP → PKA, broadly suppressing inflammatory signaling. On mast cells specifically: VPAC1 binding raises cAMP, suppressing the calcium-dependent degranulation cascade. This direct mast cell inhibition — preventing histamine, tryptase, and prostaglandin release — is the mechanistic foundation for VIP's use in MCAS.

NF-κB Suppression and Immune Shifting

VIP suppresses NF-κB activation in macrophages, dendritic cells, and T cells — reducing TNF-α, IL-6, IL-12, and IFN-γ while promoting IL-10 and Treg differentiation. This shifts the immune balance from Th1/Th17 inflammatory phenotypes toward anti-inflammatory profiles. For autoimmune-adjacent and inflammatory conditions, this immune-shifting mechanism addresses dysregulation rather than just blocking individual mediators.

Gut-Brain Axis, Circadian Regulation, and Neuroprotection

VIP is one of the primary neuromodulators in the enteric nervous system — regulating gut motility, reducing intestinal inflammation, and supporting gut barrier integrity. It's produced by neurons in the suprachiasmatic nucleus (SCN) — the master circadian clock — where it coordinates circadian rhythms. VIP deficiency disrupts circadian timing; VIP supplementation may support circadian entrainment. Additionally, VIP has neuroprotective effects via anti-inflammatory signaling and direct neuronal survival pathways.

What the research shows

STUDYCritical Care Medicine · 2022

IV vasoactive intestinal peptide (aviptadil) in critical COVID-19 respiratory failure — a 60-day randomized controlled trial

Youssef JG et al.

Multicenter RCT in 196 patients with critical COVID-19 respiratory failure (2:1 aviptadil vs. placebo). The primary endpoint was NOT met, but a prespecified secondary analysis showed roughly two-fold higher odds of survival at 60 days (OR 2.0, 95% CI 1.1–3.9, p=0.035), with an acceptable safety profile. A genuine but mixed signal — the most rigorous human VIP data in acute inflammatory illness, not a clean positive trial. (Aviptadil was not granted Emergency Use Authorization.)

View on PubMed →
STUDYJournal of Clinical Investigation · 2003

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Petkov V, Mosgoeller W, Ziesche R et al.

A small open-label pilot in 8 patients with primary pulmonary hypertension. Inhaled VIP (200 µg/day) improved 6-minute-walk distance (p<0.01), lowered mean pulmonary-artery pressure, and raised cardiac output, with no adverse effects. Early proof-of-concept for VIP as a human therapeutic — preliminary and uncontrolled, not a definitive RCT.

View on PubMed →
STUDYPeptides · 2000

Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells

Tunçel N et al.

Direct in vivo evidence that VIP inhibits mast-cell degranulation and alters their granular (histamine) content — the mechanistic basis often cited for VIP in mast-cell-activation (MCAS) / histamine-driven conditions. Shown here in a septic-shock model rather than an IgE-challenge system, so it supports the mast-cell-stabilising rationale without proving the full IgE/cAMP pathway.

View on PubMed →
WHAT THE RESEARCH SHOWS
✓KNOWN
  • ✓Direct mast cell degranulation inhibition — mechanistically confirmed (VPAC1/cAMP)
  • ✓Mortality benefit in severe COVID-19 ARDS — RCT (Aviptadil)
  • ✓Pulmonary hypertension improvement — Phase II RCT (Petkov, NEJM 2003)
  • ✓NF-κB suppression and Th1/Th17 → Th2/Treg immune shift
  • ✓Treg promotion confirmed in multiple mechanistic studies
?UNCERTAIN
  • ?RCT evidence for intranasal VIP in MCAS — no controlled trial published
  • ?Optimal intranasal dose and frequency for immune applications
  • ?Long-term safety of intranasal VIP administration
  • ?Whether intranasal delivery achieves sufficient CNS/immune concentrations
  • ?Long COVID application — observational only, no controlled data

What the community reports

VIP's community is among the most specific and medically sophisticated of any peptide in this guide — driven by people with genuine chronic inflammatory conditions rather than performance or longevity goals. MCAS and long COVID patients have done extensive research and often have medical supervision for their VIP protocols.

—MCAS: significant reduction in mast cell reaction frequency and severity — described as dramatic by some users; baseline symptom load (hives, histamine reactions, GI symptoms, cognitive symptoms) meaningfully reduced on consistent intranasal VIP protocols
—Long COVID: cognitive fog improvement, energy improvement, reduced post-exertional malaise — reported as one of the most effective interventions in this community alongside low-dose naltrexone
—Sleep quality improvement — circadian regulation mechanism; consistently noted in the CIRS/MCAS community
—GI symptom improvement — reduced motility issues, improved gut comfort
—Symptom rebound if dose is missed — consistent with the short plasma half-life and the need for regular dosing to maintain anti-inflammatory effect
—The Shoemaker Protocol context: physicians practicing CIRS treatment use intranasal VIP as a late-stage intervention with medical supervision and a structured protocol

Common misconceptions

"VIP is just a gut peptide."

REALITY

VIP was named for its vasodilatory and gut motility effects — but it's one of the most broadly distributed neuropeptides in the body, acting in the immune system, brain, lungs, reproductive system, and virtually all tissues. Its anti-inflammatory and immune-modulating roles are at least as important as its original named functions.

"The 2-minute half-life means intranasal VIP doesn't work."

REALITY

The 2-minute plasma half-life makes systemic injection impractical. Intranasal delivery bypasses systemic circulation via the olfactory-to-CNS pathway, delivering VIP directly to CNS and immune cells without requiring plasma stability. The Shoemaker protocol's 4x-daily dosing maintains local activity at CNS/immune targets.

"VIP treats MCAS by accident."

REALITY

VIP directly inhibits mast cell degranulation through a well-characterized cAMP-mediated mechanism. Mast cells express VPAC1; VIP binding suppresses calcium-dependent degranulation. This is a mechanistically grounded application, not an accidental benefit.

IMMUNE STACK

Thymosin Alpha-1 enhances adaptive immunity via T-cell maturation and NK cells — a complementary immune mechanism from the other direction. LL-37 — innate antimicrobial immune defense.

AI RESEARCHER PREVIEW
I have MCAS and want to try intranasal VIP. What protocol should I follow and what should I track?
For MCAS specifically, VIP is one of the most mechanistically well-grounded interventions available — direct VPAC1-mediated mast cell degranulation inhibition is exactly the mechanism MCAS needs. Here's how to approach it. Protocol context first: if you're familiar with the Shoemaker Protocol for CIRS, VIP is used as a late-stage intervention after prior steps (binders, VIP-normalizing interventions, etc.). If you're using VIP specifically for MCAS without the full Shoemaker context, that's a different starting point and ideally involves a physician who is familiar with mast cell activation syndrome. Standard Shoemaker intranasal protocol: 50 mcg per administration, 4 times daily — morning, midday, afternoon, evening. This 4x-daily schedule is specifically designed around the ~2-minute plasma half-life: you need frequent dosing to maintain active VIP levels at CNS/immune targets throughout the day. If that frequency is impractical to start, 2–3x daily is a reasonable titration entry point — assess tolerance and symptom response before committing to 4x daily. Start lower: some practitioners recommend beginning at 50 mcg 2x daily for the first week to establish tolerability before escalating to the full protocol. Side effects to watch: VIP is generally well-tolerated intranasally. Some users report mild flushing or transient nausea shortly after administration — this is consistent with VIP's vasodilatory and gut motility mechanisms and typically diminishes. What to track in PepperLedger for MCAS: daily symptom load (your personal MCAS symptom composite — hives, GI symptoms, brain fog, fatigue, pain — on a consistent 0–10 scale); specific reaction events and severity; sleep quality; energy. The most important tracking principle: establish a 2-week symptom baseline before starting VIP so you have clear before/after data. MCAS presentations are heterogeneous — what improves for one person may not be your primary symptom cluster. Important qualification: if you have any autoimmune condition in addition to MCAS, medical supervision is more important — VIP's immune-shifting effects need to be evaluated in that context. And VIP is a complement to existing MCAS management (antihistamines, mast cell stabilizers, low-histamine diet), not a replacement for it.
CONTINUE IN THE APP

Open PepperLedger to track your VIP protocol →

Free to join. No credit card. Ask the Researcher about your VIP protocol once you're in.

Free to join · No credit card · 23-day Pro trial included

Authoritative sources

Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.

PepperLedger

Educational tool — not medical advice. PepperLedger is a logging and information tool for adults managing their own protocols. It does not prescribe, diagnose, or treat anything. Always work with a qualified healthcare provider for medical decisions.

VIP is not FDA-approved for MCAS, long COVID, or immune applications. Medical supervision recommended, especially with autoimmune conditions or Shoemaker Protocol. Educational tool — not medical advice.

© 2026 Realee AI · PepperLedger